AstraZeneca debuts Nexium savings prog

AstraZeneca's US subsidiary has announced the enhancements to the Purple Plus Program for patients with gastroesophageal reflux disease who are prescribed Nexium (esomeprazole). This patient support program is designed to make the drug more affordable for patients through instant rebates, and to provide educational tools that can assist patients in staying adherent to their prescribed therapy.

"Nexium is a very important treatment option for patients with GERD because of its proven efficacy in healing damage to the esophagus caused by acid reflux," said Doug Levine, executive director in clinical development for AstraZeneca. "As part of our long-standing commitment to positively impact the gastrointestinal health of patients with acid-related diseases, we are pleased to offer a program that can make Nexium as prescribed by health care professionals, more affordable to patients. The support and education components of Purple Plus can help patients appropriately partner with their health care professionals in managing their disease through recommended treatment interventions, which optimizes the chances for achieving the best possible outcomes," he added.